PEPTIDE GUIDE

What Is Ipamorelin?

Ipamorelin is a synthetic peptide made from five amino acids. It activates the ghrelin receptor, a signalling switch on certain cells that normally responds to the hormone ghrelin. In early research, this caused the pituitary, a small gland beneath the brain, to release growth hormone.

Ipamorelin is widely promoted online for muscle growth, fat loss, recovery, sleep and anti-ageing. Human research has not established those uses. It is not an approved medicine in the United States, and the evidence is much smaller than online descriptions often suggest.

Research statusInvestigational peptide with limited human evidence
Development codeNNC 26-0161
Peptide typeFive-amino-acid ghrelin-receptor agonist
Human evidenceLimited clinical research
Last reviewedSeptember 2026
THE SHORT ANSWER

Ipamorelin is an investigational growth-hormone secretagogue, meaning a substance that prompts the body to release growth hormone. Early studies showed that it could produce a short rise in growth hormone. A later Phase 2 study, an early clinical test of whether a treatment appears to work while researchers continue collecting safety information, examined whether it could help the bowel recover after surgery. Its main result was not strong enough to rule out chance as a reasonable explanation. There is no reliable clinical evidence that ipamorelin builds muscle, reduces body fat, improves sleep or slows ageing in otherwise healthy people.

What does the name mean?

Ipamorelin was originally identified during research at Novo Nordisk A/S, the Danish pharmaceutical company now known for medicines including insulin and semaglutide products. Its development code was NNC 26-0161.

The molecule is a pentapeptide. “Penta” means five, so a pentapeptide is simply a chain containing five amino acids, the small building blocks used to make peptides and proteins.

Ipamorelin was designed as a growth-hormone-releasing peptide. That description can sound as though it contains growth hormone. It does not. It sends a signal that can prompt the body to release some of its own stored growth hormone.

How does ipamorelin work?

Ipamorelin activates the growth hormone secretagogue receptor, usually shortened to GHSR. A receptor is a protein that receives a biological signal and changes how a cell behaves. The receptor is also commonly called the ghrelin receptor because ghrelin, a hormone involved in hunger, digestion and growth-hormone release, is its natural signal.

After the receptor is activated, the pituitary gland can release growth hormone into the blood. The pituitary is a small gland beneath the brain that helps control several hormones.

Growth hormone supports normal growth in children and helps regulate body tissues, metabolism and repair throughout life. It can also prompt the liver and other tissues to produce insulin-like growth factor 1, normally shortened to IGF-1. IGF-1 is another hormone involved in growth and tissue activity.

These biological roles do not prove that artificially increasing the signal improves health, recovery or ageing. A measurable hormone response is evidence that a molecule affects its target. It is not automatically evidence of a useful clinical outcome.

Why was ipamorelin described as selective?

The original research compared ipamorelin with other experimental growth-hormone-releasing peptides. In rats and pigs, ipamorelin stimulated growth-hormone release without producing the same measurable rises in adrenocorticotropic hormone and cortisol seen with some related compounds.

Adrenocorticotropic hormone, usually called ACTH, tells the adrenal glands to release cortisol. Cortisol helps the body respond to stress and regulate metabolism. Researchers therefore described ipamorelin as selective for growth-hormone release.

There are two important limits. Much of this comparison came from animals, and “selective” does not mean that the compound has no other effects or is proven safe. It describes what researchers measured under the conditions used.

What did the first human study show?

A 1999 study examined how ipamorelin moved through the body and how growth hormone responded. This type of early human research resembles Phase 1 research, which usually asks about initial safety, how the body handles a substance and whether it produces the expected biological response.

The researchers studied five intravenous infusion levels. Intravenous means that the substance was delivered into a vein. Eight healthy men were studied at each level, giving 40 participants across the groups. Each infusion lasted 15 minutes, and the researchers measured ipamorelin and growth-hormone levels in the blood to understand the immediate response.

Infusion level used in the studyHow it was givenResearch purpose
4.21 nanomoles per kilogramInfused over 15 minutesExamine response at the lowest level
14.02 nanomoles per kilogramInfused over 15 minutesMeasure increasing exposure and hormone response
42.13 nanomoles per kilogramInfused over 15 minutesMeasure increasing exposure and hormone response
84.27 nanomoles per kilogramInfused over 15 minutesMeasure increasing exposure and hormone response
140.45 nanomoles per kilogramInfused over 15 minutesExamine response at the highest level

A nanomole is a measurement of the number of molecules rather than their weight. “Per kilogram” means the research amount was adjusted to body weight.

Blood measurements showed that ipamorelin caused a growth-hormone response. The researchers used pharmacokinetic and pharmacodynamic modelling. Pharmacokinetics describes what the body does to a substance over time, while pharmacodynamics describes what the substance does to the body.

This study helps explain ipamorelin's immediate biological activity. It did not test muscle gain, body-fat reduction, sleep, injury recovery or long-term safety. The administration levels above are historical research details, not personal dosing guidance.

Why was ipamorelin studied after bowel surgery?

Researchers later explored whether ghrelin-receptor activation could help the digestive tract start moving again after bowel surgery.

Postoperative ileus is a temporary slowing or stopping of normal bowel movement after an operation. It can delay eating, cause discomfort and keep someone in hospital for longer. Animal research suggested that ipamorelin could speed movement through the stomach and bowel, so a human proof-of-concept study followed.

A proof-of-concept study is an early clinical test asking whether an idea shows enough promise to justify larger research. It is not designed to provide the final answer expected from a large confirmatory trial.

What did the Phase 2 surgical study find?

The published Phase 2 study enrolled adults having part of their bowel removed. Phase 2 research asks whether a treatment appears to work in people with the target condition, while also collecting safety information and exploring the administration used in research.

The study was randomised and placebo-controlled. Randomised means participants were assigned to groups by chance, which helps prevent differences between the groups from biasing the result. A placebo is an inactive comparison designed to resemble the study treatment, allowing researchers to ask whether any difference is greater than might occur without the active compound.

Participants received an intravenous ipamorelin infusion or placebo after surgery and were studied for up to seven days. The main result the researchers planned to assess was the time until a person could tolerate their first meal.

The median time was 25.3 hours with ipamorelin and 32.6 hours with placebo. A median is the middle result when all results are put in order. Although the numerical difference favoured ipamorelin, the probability value was 0.15. This did not reach the usual threshold researchers use to rule out chance as a reasonable explanation.

In plain English, the study did not provide reliable evidence that ipamorelin shortened the time to the first tolerated meal. It was also too small and narrowly focused to support the wellness claims now attached to the peptide online.

Has ipamorelin been through Phase 3 trials?

No convincing published Phase 3 programme for ipamorelin was identified in preparing this guide. Phase 3 normally tests a proposed medicine in much larger groups to confirm benefits and gather more safety evidence before a possible approval application.

Ipamorelin is sometimes confused with ulimorelin, another experimental ghrelin-receptor agonist studied after bowel surgery. Ulimorelin reached Phase 3, but it is a different molecule. Its failed Phase 3 results should not be presented as an ipamorelin trial, just as its earlier findings cannot establish an ipamorelin benefit.

Is ipamorelin FDA approved?

No. The US Food and Drug Administration, usually called the FDA, has not approved ipamorelin as a medicine for any condition.

FDA approval means the regulator has reviewed evidence for a specific finished product, manufacturing process, intended population and medical use. It does not apply merely because a chemical name appears on a vial or website.

There is no approved ipamorelin product for growth-hormone deficiency, muscle growth, fat loss, injury recovery, sleep or anti-ageing. Products sold as “research use only” are not approved medicines and should not be treated as equivalent to material used in controlled studies.

What benefits are claimed, and what does the evidence support?

Common claimWhat the evidence actually shows
Raises growth hormoneA short-term hormone response was demonstrated in early research
Builds muscleNo adequate clinical trial has established meaningful muscle gain in healthy people
Reduces body fatNo adequate clinical trial has established fat loss as an ipamorelin treatment effect
Improves recoveryNo reliable human trial has shown improved recovery from exercise or injury
Improves sleepNo adequate clinical evidence establishes a sleep benefit
Slows ageingNo clinical trial shows that ipamorelin slows ageing or extends life
Restarts the bowel after surgeryA small Phase 2 trial did not show a statistically reliable improvement in its main measure

Hormone changes are sometimes used as a shortcut to market all the outcomes associated with growth hormone. That skips the clinical question. Researchers must measure whether people actually gain the proposed benefit and whether any gain outweighs the risks.

What side effects and risks are known?

The human evidence is too limited to produce the kind of complete side-effect profile available for an approved medicine. Small, short studies can identify some immediate reactions, but they may miss rare problems and effects that emerge after longer use.

Changing the growth-hormone and IGF-1 system could plausibly affect blood sugar, fluid balance, joints, nerves and the growth of sensitive tissues. These concerns come partly from established knowledge about excessive growth-hormone activity and approved growth-hormone treatment. They are not a substitute for direct ipamorelin safety trials.

Claims that ipamorelin is safer because it is “selective” go beyond the evidence. The original selectivity finding concerned certain hormone measurements, mainly in animals. It did not prove long-term safety in people.

Anyone using an online product also faces risks separate from the molecule itself. It may contain the wrong substance or amount, be contaminated or not be sterile.

Is ipamorelin the same as growth hormone?

No. Growth hormone is the hormone released by the pituitary gland. Ipamorelin is a signal intended to prompt that release.

The difference does not make ipamorelin a harmless or “natural” substitute. Both approaches can alter the same biological system, and ipamorelin has not passed the evidence and manufacturing review required for an approved product.

How is ipamorelin different from sermorelin?

Sermorelin is an analogue of growth hormone-releasing hormone, the natural hormone that tells the pituitary to release growth hormone. An analogue is a modified molecule designed to resemble a natural signal.

Ipamorelin works through the ghrelin receptor instead. The pathways can interact, but that does not establish that combining the molecules is effective or safe. They should not be compared by milligrams because they are different molecules acting at different receptors.

How is ipamorelin different from CJC-1295?

CJC-1295 is a longer-acting experimental analogue of growth hormone-releasing hormone. Ipamorelin is a ghrelin-receptor agonist. An agonist is a molecule that switches on a receptor.

Online discussions often describe combining them, sometimes called “stacking”. This guide does not advise combining these substances, and controlled evidence has not established the safety or benefit of popular combinations sold outside approved treatment.

Is ipamorelin prohibited in sport?

Growth-hormone-releasing factors and related secretagogues are prohibited under anti-doping rules. Athletes should use the current World Anti-Doping Agency list and their governing body's rules rather than relying on product marketing or informal advice.

The fact that a substance is sold openly does not make it permitted in organised sport.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is ipamorelin a peptide?

Yes. It is a synthetic chain of five amino acids, making it a pentapeptide.

Does ipamorelin increase growth hormone?

Early studies recorded a short-term rise in growth hormone. That biological response does not prove the broader benefits promoted online.

Does ipamorelin increase IGF-1?

Growth hormone can stimulate production of IGF-1, but the limited ipamorelin research does not establish a predictable long-term IGF-1 response or a clinical benefit for healthy users.

Is ipamorelin approved for muscle growth or fat loss?

No. It is not FDA approved for any use, and adequate human trials have not established either claim.

Was ipamorelin successful in clinical trials?

It produced the expected growth-hormone response in early research. The later Phase 2 surgical study did not show a statistically reliable improvement in its main outcome.

Is ipamorelin the same as ipamorelin acetate?

Ipamorelin acetate is ipamorelin combined with acetate to form a salt used in a research material or product. Naming this form does not establish the product's quality, approval or whether it matches the material used in clinical trials.

Can ipamorelin be combined with CJC-1295?

This guide provides no combination advice. Widely discussed combinations have not been supported by the kind of controlled human evidence needed to establish benefit and safety.

What is an ipamorelin cycle?

“Cycle” is an informal term for a period of self-directed use. It is not a clinically established treatment schedule, and this guide does not provide one.

What the evidence supports today

Ipamorelin clearly has biological activity. Early research showed that it can activate the ghrelin receptor and trigger growth-hormone release. That makes it scientifically interesting.

The evidence does not support the much larger collection of claims attached to it online. Human research is limited, the small surgical trial did not establish its main proposed benefit, and no approved ipamorelin medicine exists.

Ipamorelin is an investigational growth-hormone-releasing peptide with demonstrated short-term hormone effects, limited clinical testing and no proven role in muscle building, fat loss, recovery, sleep or anti-ageing.

RESEARCH AND MEDICAL NOTICE

This article is educational and does not provide medical advice, dosing, injection, reconstitution, cycling, stacking or purchasing instructions. Administration levels appear only to explain documented research. Ipamorelin is not an FDA-approved medicine. Questions about hormone health or treatment should be discussed with a qualified healthcare professional.

Research reviewed through September 2026.